Biomarker evidence of neurodegeneration in chronic kidney disease, in a general population
Anna Dittrich(Sahlgrenska University Hospital), Silke Kern(University of Gothenburg), Joel Simrén(University of Gothenburg), Kaj Blennow(Sahlgrenska University Hospital), Alejandra Machado(Sahlgrenska University Hospital), Anna Zettergren(University of Gothenburg), Ingmar Skoog(Sahlgrenska University Hospital), Michael Schöll(Wallenberg Wood Science Center), Henrik Zetterberg(University of Wisconsin–Madison), Sara Shams(Karolinska University Hospital), Eric Westman(Wellcome Centre for Human Neuroimaging), Nicholas J. Ashton(King's College London)
Cited by 0
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k